Loch D - Search Results

1

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM. Byron SA, et al. Among authors: loch d. Neoplasia. 2013 Aug;15(8):975-88. doi: 10.1593/neo.121106. Neoplasia. 2013. PMID: 23908597 Free PMC article.

2

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Byron SA, Loch DC, Pollock PM. Byron SA, et al. Among authors: loch dc. Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806. Int J Gynecol Cancer. 2012. PMID: 23060048

3

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM. Byron SA, et al. Among authors: loch dc. Mol Cancer. 2012 Oct 5;11:75. doi: 10.1186/1476-4598-11-75. Mol Cancer. 2012. PMID: 23039341 Free PMC article.

4

Lineage-specific biomarkers predict response to FGFR inhibition.

Loch DC, Pollock PM. Loch DC, et al. Cancer Discov. 2012 Dec;2(12):1081-3. doi: 10.1158/2159-8290.CD-12-0486. Cancer Discov. 2012. PMID: 23230185 Free PMC article.

5

Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat.

Loch D, Chan V, Hoey A, Brown L. Loch D, et al. Basic Clin Pharmacol Toxicol. 2009 Oct;105(4):262-70. doi: 10.1111/j.1742-7843.2009.00440.x. Epub 2009 Jul 2. Basic Clin Pharmacol Toxicol. 2009. PMID: 19583711 Free article.

6

Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.

Loch D, Levick S, Hoey A, Brown L. Loch D, et al. J Cardiovasc Pharmacol. 2006 Mar;47(3):396-404. doi: 10.1097/01.fjc.0000210072.48991.f6. J Cardiovasc Pharmacol. 2006. PMID: 16633082

7

Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.

Levick S, Loch D, Rolfe B, Reid RC, Fairlie DP, Taylor SM, Brown L. Levick S, et al. Among authors: loch d. J Immunol. 2006 Jun 1;176(11):7000-7. doi: 10.4049/jimmunol.176.11.7000. J Immunol. 2006. PMID: 16709861

8

Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.

Loch D, Hoey A, Brown L. Loch D, et al. Clin Exp Hypertens. 2006 Jul;28(5):475-88. doi: 10.1080/10641960600798754. Clin Exp Hypertens. 2006. PMID: 16820344 Free article.

9

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase.

Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Loch D, et al. Cell Biochem Biophys. 2007;47(1):87-98. doi: 10.1385/cbb:47:1:87. Cell Biochem Biophys. 2007. PMID: 17406062 Free PMC article.

10

Cardiovascular changes during maturation and ageing in male and female spontaneously hypertensive rats.

Chan V, Fenning A, Levick SP, Loch D, Chunduri P, Iyer A, Teo YL, Hoey A, Wilson K, Burstow D, Brown L. Chan V, et al. Among authors: loch d. J Cardiovasc Pharmacol. 2011 Apr;57(4):469-78. doi: 10.1097/FJC.0b013e3182102c3b. J Cardiovasc Pharmacol. 2011. PMID: 21283019

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters